Table 3. Univariate analysis of clinical, biological and therapeutic factors.

	No. of patients	% 5-year local control	P-value	% 5-year DFS	P-value
Age
⩽68/>68 years	48/50	68/74	0.44	55/72	0.08
T category (UICC 1997)
T1–2/T3–4	60/38	81/55	0.006	73/49	0.01
N category
N0/N1–3	74/24	80/44	0.0003	74/33	<0.0001
Chemotherapy
No/yes	47/51	80/65	0.16	55/77	0.18
Overall treatment time
⩽72/>72 days	50/48	84/58	0.008	77/50	0.004
Immunostaining (CI)
Cyclin E low/high	48/50	74 (62–87)/69 (55–82)	0.54	67 (53–81)/61 (47–75)	0.56
Cyclin D1 low/high	65/33	73 (62–84)/68 (51–84)	0.56	67 (55–78)/57 (39–75)	0.40
p21 low/high	34/64	66 (49–82)/74 (63–85)	0.46	59 (41–76)/66 (54–78)	0.50
p53 low/high	42/56	78 (66–91)/66 (53–79)	0.22	75 (62–88)/55 (42–69)	0.07
Mib-1 low/high	58/40	75 (64–86)/66 (51–81)	0.37	67 (54–80)/59 (44–75)	0.30

DFS=disease-free survival, UICC=Union International Contre le Cancer; CI=confidence interval.